Anchiano Therapeutics welcomes Efrat Makov to its Board of Directors

– USA, MA – Anchiano Therapeutics Ltd. (TASE:ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of Ms. Efrat Makov to its Board of Directors.

“We warmly welcome Efrat to our Board of Directors,” said Frank Haluska, M.D., Ph.D, President and Chief Executive Officer of Anchiano Therapeutics. “She will be a tremendous asset to our Board as she brings to Anchiano deep financial experience as the former chief financial officer of publicly-traded companies in the US and Israel, as well as her positions as a Director in publicly traded-health care companies in Israel. Her experience, insight, and record of accomplishment and success will prove invaluable as Anchiano progresses to the next stage in its evolution.”

Ms. Makov noted, “I am pleased to join this dynamic Board and look forward to working with Anchiano’s management and helping the company meet the exciting opportunities that lie ahead.”

About Efrat Makov

Ms. Efrat Makov joins the Board after having served as the Chief Financial Officer of Alvarion Ltd. Prior to Alvarion, Ms. Makov served as the Chief Financial Officer of Aladdin Knowledge Systems Ltd. where she was responsible for the finance, operations, information systems and human resources functions. She served as Vice President of Finance at Check Point Software Technologies Ltd. and as Director of Finance for NUR Macroprinters Ltd., after having spent seven years in public accounting with Arthur Andersen in various senior financial positions in its New York, London and Tel Aviv offices. She serves as a Director on the Board of BioLight Life Sciences Ltd. and its subsidiaries. She is an Israel and U.S. Certified Public Accountant. Ms. Makov holds a B.A. in Accounting and Economics from Tel Aviv University.

About Anchiano Therapeutics

Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel. The Company’s most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>